Companies
Inari Agriculture
720 million cumulative funding; SEEDesign™ platform combines multiplex CRISPR-CasS editing with AI predictive design; soybeans first to market targeting +10–20% yield and -40% nitrogen use.
- Country
- United States
CRISPR
US
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| crop-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisefsamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Over $720 million in cumulative equity funding | inari.com |
| Regulatory approval | USDA does not consider gene-edited soybean lines described in 2025 inquiry to be regulated under 7 CFR part 340 | direct.aphis.usda.gov |
| Production site | Cambridge, Massachusetts; West Lafayette, Indiana; Ghent, Belgium | inari.com · causeartist.com · prnewswire.com |
| Headcount | More than 300 employees (as of 2024/2025 reports) or 221 employees (LinkedIn data) medium confidence | inari.com · causeartist.com · prnewswire.com |
| Revenue | Pre-meaningful-revenue; early-commercialization stage medium confidence | menfem.com · siliconvalleyinvestclub.com |
Independent sources: causeartist.com · direct.aphis.usda.gov · menfem.com · prnewswire.com · siliconvalleyinvestclub.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Precision Plant Breeding & CRISPR Crop Editing | crop-biotech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.